VYGR (STOCKS)
Voyager Therapeutics, Inc. Common Stock
$3.420000
-0.230000 (-6.30%)
Prev close: $3.650000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alfred W. Sandrock
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $189.60M
- Employees
- 172
- P/E (TTM)
- -1.68
- P/B (TTM)
- 0.92
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.47 | $-0.53 | +0.0608 | +11.45% |
|
Jun 2025 (Q2)
|
$-0.57 | $-0.54 | -0.0339 | -6.32% |
|
Mar 2025 (Q1)
|
$-0.53 | $-0.46 | -0.0720 | -15.72% |
|
Dec 2024 (Q4)
|
$-0.59 | $-0.37 | -0.2163 | -57.88% |
Financial Statements
| Revenues | $31.32M |
| Benefits Costs and Expenses | $157.38M |
| Costs And Expenses | $157.38M |
| Nonoperating Income/Loss | $14.15M |
| Operating Expenses | $171.53M |
| Research and Development | $134.31M |
| Other Operating Expenses | $37.22M |
| Operating Income/Loss | -$140.21M |
| Income/Loss From Continuing Operations After Tax | -$126.78M |
| Income/Loss From Continuing Operations Before Tax | -$126.06M |
| Income Tax Expense/Benefit | $719.00K |
| Net Income/Loss | -$126.78M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$126.78M |
| Net Income/Loss Available To Common Stockholders, Basic | -$126.78M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.17 |
| Diluted Earnings Per Share | -$2.17 |
| Basic Average Shares | 117,415,134 |
| Diluted Average Shares | 117,415,134 |
| Assets | $288.31M |
| Current Assets | $219.59M |
| Cash | $229.00M |
| Accounts Receivable | $3.19M |
| Noncurrent Assets | $68.73M |
| Fixed Assets | $13.29M |
| Other Non-current Assets | $55.44M |
| Liabilities | $68.49M |
| Current Liabilities | $35.50M |
| Accounts Payable | $2.12M |
| Wages | $6.22M |
| Other Current Liabilities | $27.16M |
| Noncurrent Liabilities | $32.99M |
| Equity | $219.83M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $219.83M |
| Liabilities And Equity | $288.31M |
| Net Cash Flow From Operating Activities | -$116.73M |
| Net Cash Flow From Operating Activities, Continuing | -$116.73M |
| Net Cash Flow From Investing Activities | $50.82M |
| Net Cash Flow From Investing Activities, Continuing | $50.82M |
| Net Cash Flow From Financing Activities | $1.25M |
| Net Cash Flow From Financing Activities, Continuing | $1.25M |
| Net Cash Flow | -$64.66M |
| Net Cash Flow, Continuing | -$64.66M |
| Comprehensive Income/Loss | -$126.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$126.74M |
| Other Comprehensive Income/Loss | $40.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $40.00K |